Article Details
Retrieved on: 2024-08-14 13:51:24
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The European Commission on Wednesday signed off on AstraZeneca's combination regimen of Imfinzi (durvalumab) and Lynparza (olaparib) for the treatment ...
Article found on: www.pharmalive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here